Bayer makes first move into condensates
| Details | Nat Biotechnol. 2020 Jan;38(1):5. doi: 10.1038/s41587-019-0386-6. |
|---|---|
| Published | January 30, 2020 |
| DOI | 10.1038/s41587-019-0386-6 |
| Topics | |
| Keywords | |
| Source | Read whole story |
German pharma Bayer has signed a $100 million deal with Dewpoint Therapeutics to jointly pursue biomolecular condensates for drug discovery. The companies will combine Dewpoint’s condensates expertise with Bayer’s small-molecules library to discover drugs for heart diseases and gynecological indications…
Join the conversation